Researchers H. Braak and E. Braak proposed a staging of neuropathological Tau deposition in the brain through immunohistochemical staining (Braak and Braak, 1991), which has been optimized over time to allow pathologists to more consistently judge the stage of Tau accumulation and whether AD should be diagnosed in a patient post-mortem (Braak et al., 2006). The gene discussed is MAPT; the disease is Alzheimer disease.